Two cases of uterus-conserving treatment for early stage endometrial cancer

The aim of study is to present two successful cases of conservative surgical treatment of women with early-stage endometrial cancer who desired to have fertility in the two cases. A 32-year-old nulligravid woman had Stage IA endometrial cancer which was a 1.5-cm sized lesion confined to the left fundal side of the uterus. The other 35-year-old nulligravid woman had a 2-cm sized lesion suspicious for deep myometrial involvement suggesting Stage IB endometrial cancer. The women underwent hysteroscopic complete resection of tumor with safe resection margin just after laparoscopic tubal ligation, followed by insertion of a progesterone-releasing intrauterine device. The patients have no evidence of recurrence for 26 months and 27 months of follow-up, respectively. Hysteroscopic complete resection of tumor with safe margin combined with bilateral tubal ligation, followed by a progesterone-releasing intrauterine device could be a good option for early-stage endometrial cancer.

Endometrial cancer; Hysteroscopy; Laparoscopy; Tubal ligation.

[1] Baker J., Obermair A., Gebski V., Janda M.: “Efficacy of oral or intrauterine device-delivered progestin in patients with complex endometrial hyperplasia with atypia or early endometrial adenocarcinoma: a meta-analysis and systematic review of the literature”. Gynecol. Oncol., 2012, 125, 263.

[2] Gadducci A., Spirito N., Baroni E., Tana R., Genazzani A.R.: “The fertility-sparing treatment in patients with endometrial atypical hyperplasia and early endometrial cancer: a debated therapeutic option”. Gynecol. Endocrinol., 2009, 25, 683.

[3] Polyzos N.P., Mauri D., Tsioras S., Messini C..I, Valachis A., Messinis I.E.: “Intraperitoneal dissemination of endometrial cancer cells after hysteroscopy: a systematic review and meta-analysis”. Int. J. Gynecol. Cancer., 2010, 20, 261.

[4] Gallos I.D., Yap J., Rajkhowa M., Luesley D.M., Coomarasamy A., Gupta J.K.: “Regression, relapse, and live birth rates with fertilitysparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis”. Am. J. Obstet. Gynecol., 2012, 207, 266.

[5] Gracia C.R., Sammel M.D., Freeman E., Prewitt M., Carlson C., Ray A., et al.: “Impact of cancer therapies on ovarian reserve”. Fertil. Steril., 2012, 97, 134.

[6] Laurelli G., Di Vagno G., Scaffa C., Losito S., Del Giudice M., Greggi S.: “Conservative treatment of early endometrial cancer: preliminary results of a pilot study”. Gynecol. Oncol., 2011, 120, 43.

[7] Mazzon I., Corrado G., Masciullo V., Morricone D., Ferrandina G., Scambia G.: “Conservative surgical management of stage IA endometrial carcinoma for fertility preservation”. Fertil. Steril., 2010, 93, 1286.

[8] Gallos I.D., Krishan P., Shehmar M., Ganesan R., Gupta J.K.: “LNGIUS versus oral progestogen treatment for endometrial hyperplasia: a long-term comparative cohort study”. Hum. Reprod., 2013, 28, 2966.

[9] Orbo A., Vereide A., Arnes M., Pettersen I., Straume B.: “Levonorgestrel-impregnated intrauterine device as treatment for endometrial hyperplasia: a national multicentre randomised trial”. BJOG, 2014, 121, 477.